newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

  • AIM ImmunoTech spotlighted a BioTuesdays interview with CEO Thomas K. Equels regarding Ampligen's potential as a maintenance therapy for metastatic pancreatic cancer following first-line chemotherapy.
  • The company is evaluating Ampligen in combination with AstraZeneca's Imfinzi in the Phase 2 DURIPANC trial, which aims to convert "cold" tumors into an immunologically active state to enhance checkpoint inhibitor efficacy.
  • Final dosing for the DURIPANC trial is complete, & AIM awaits reporting of primary & secondary endpoints to guide the path toward pivotal development.
  • Exploratory analyses from the Netherlands-approved Named Patient Program showed a median overall survival of 34.8 months for 39 patients with a neutrophil-to-lymphocyte ratio below 4.5 who received Ampligen after FOLFIRINOX.
  • AIM holds U.S. & EU orphan drug designations for Ampligen in pancreatic cancer & has patents covering its use in combination with checkpoint inhibitors.
  • The company is exploring potential financing or pharmaceutical partnership pathways to support a future pivotal Phase 3 study.
  • Forward-looking statements in the press release include risks regarding trial outcomes, regulatory approvals, funding, & the ability to prove Ampligen's efficacy in human clinical trials.